Grifols | GRFS - Operating Profit

Stock Price
9.07
Daily Change
0 0%
Monthly
-1.41%
Yearly
22.90%
Q1 Forecast
9.14

Grifols reported EUR411.56M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Arca Biopharma USD -25.09M 5.23M Mar/2025
aTyr Pharma USD -26.74M 6.43M Sep/2025
Bio Path USD -3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Capricor Therapeutics USD -24.98M 17.28M Mar/2025
Cara Therapeutics USD -2.39M 3.49M Mar/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Immunic USD -25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024